{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T05:35:52Z","timestamp":1788327352728,"version":"build-2803163510"},"reference-count":43,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2023,1,10]],"date-time":"2023-01-10T00:00:00Z","timestamp":1673308800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"the Italian Ministry of Health\u2014Ricerca Corrente, Annual Program 2023"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>(1) Introduction: Small cell lung cancer (SCLC) is an aggressive tumor type, accounting for about 15% of all lung cancers. Radiotherapy (RT) plays a fundamental role in both early and advanced stages. Currently, in advanced disease, the use of consolidative chest RT should be recommended for patients with good response to platinum-based first-line chemotherapy, but its use has not yet been standardized. The present prospective study aims to evaluate the pattern of care of consolidative chest RT in patients with advanced stage SCLC, and its effectiveness in terms of disease control and tolerability. (2) Materials and methods: This study was a multicenter prospective observational trial, proposed and conducted within the AIRO lung study group to evaluate the pattern of care of consolidative chest RT after first-line chemotherapy in patients with advanced SCLC. The patient and tumor characteristics, doses, fractionation and volumes of thoracic RT and prophylactic cranial irradiation (PCI), as well as the thoracic and extrathoracic response to the treatment, toxicity and clinical outcomes, were collected and analyzed. (3) Results: From January 2017 to December 2019, sixty-four patients were enrolled. Median follow-up was 33 months. The median age was 68 years (range 42\u201381); 38 patients (59%) were male and 26 (41%) female. Carboplatin + etoposide for 6 cycles was the most commonly used first-line therapeutic scheme (42%). With regard to consolidative chest RT, 56% of patients (35) received 30 Gy in 10 factions and 16 patients (26%) received 45 Gy in 15 sessions. The modulated intensity technique was used in 84.5% of cases, and post-chemotherapy macroscopic residual disease was the target volume in 87.5% of patients. Forty-four patients (69%) also underwent PCI. At the last follow-up, over 60% of patients did not experience chest disease progression, while 67% showed extrathoracic progression. At the first radiological evaluation after RT, complete response and stable disease were recorded in 6% and 46% of the cases, respectively. Two patients had a long-term complete response to the combined treatment. The brain was the first site of extrathoracic progression in 28%. 1y and 2y OS and PFS were 67%, 19%, 28% and 6%, respectively. Consolidative chest RT was well-tolerated in the majority of patients; it was interrupted in three cases (due to G2 pulmonary toxicity, disease progression and clinical decay, respectively). Only 1 patient developed G3 asthenia. (4) Conclusions: Consolidative chest RT has been shown to be useful in reducing the risk of thoracic disease progression and is absolutely well-tolerated in patients with advanced stage SCLC with good response after first-line chemotherapy. Among the Italian centers that participated in this study, there is still variability in the choice of fractionation and target volumes, although the guidelines contain clear recommendations. The aim of future research should be to clarify the role and modalities of chest RT in the era of immunotherapy in advanced-stage SCLC.<\/jats:p>","DOI":"10.3390\/cancers15020434","type":"journal-article","created":{"date-parts":[[2023,1,10]],"date-time":"2023-01-10T01:57:48Z","timestamp":1673315868000},"page":"434","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Thoracic Radiotherapy in Extensive Disease Small Cell Lung Cancer: Multicenter Prospective Observational TRENDS Study"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8890-3460","authenticated-orcid":false,"given":"Salvatore","family":"Cozzi","sequence":"first","affiliation":[{"name":"Radiation Oncology Unit, Azienda USL-IRCCS di Reggio Emilia, 42123 Reggio Emilia, Italy"},{"name":"Radiation Oncology Department, Centre L\u00e8on B\u00e8rard, 693736 Lyon, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessio","family":"Bruni","sequence":"additional","affiliation":[{"name":"Radiation Therapy Unit, Department of Oncology and Hematology, University Hospital of Modena, 41125 Modena, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Paola","family":"Ruggieri","sequence":"additional","affiliation":[{"name":"Radiation Oncology Unit, Azienda USL-IRCCS di Reggio Emilia, 42123 Reggio Emilia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7275-7908","authenticated-orcid":false,"given":"Paolo","family":"Borghetti","sequence":"additional","affiliation":[{"name":"Radiation Oncology Department, ASST Spedali Civili and University of Brescia, 25123 Brescia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vieri","family":"Scotti","sequence":"additional","affiliation":[{"name":"Radiation Oncology Unit, Oncology Department AOU Careggi Firenze, 50134 Florence, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1142-2439","authenticated-orcid":false,"given":"Davide","family":"Franceschini","sequence":"additional","affiliation":[{"name":"Radiation Therapy Unit, IRCCS Humanitas Cancer Center, 20089 Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1889-4578","authenticated-orcid":false,"given":"Michele","family":"Fiore","sequence":"additional","affiliation":[{"name":"Radiation Oncology, Campus Bio-Medico University, Fondazione Policlinico Universitario Campus Bio-Medico, 00128 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Taraborrelli","sequence":"additional","affiliation":[{"name":"Radiation Oncology Unit, \u201cSS Annunziata\u201d Hospital, \u201cG. D\u2019Annunzio\u201d University, 66100 Chieti, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabrizio","family":"Salvi","sequence":"additional","affiliation":[{"name":"Radiation Oncology Unit, Bellaria Hospital, 40139 Bologna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Galaverni","sequence":"additional","affiliation":[{"name":"Radiotherapy Unit, Azienda Ospedaliera Universitaria, 43126 Parma, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luisa","family":"Savoldi","sequence":"additional","affiliation":[{"name":"Research and Statistics Infrastructure, Azienda Unit\u00e0 Sanitaria Locale\u2013IRCCS di Reggio Emilia, 42123 Reggio Emilia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Braglia","sequence":"additional","affiliation":[{"name":"Research and Statistics Infrastructure, Azienda Unit\u00e0 Sanitaria Locale\u2013IRCCS di Reggio Emilia, 42123 Reggio Emilia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0768-3249","authenticated-orcid":false,"given":"Andrea","family":"Botti","sequence":"additional","affiliation":[{"name":"Medical Physics Unit, Azienda USL-IRCCS di Reggio Emilia, 42123 Reggio Emilia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastiano","family":"Finocchi Ghersi","sequence":"additional","affiliation":[{"name":"Radiation Oncolgy Unit, AOU Sant\u2019Andrea, Facolt\u00e0 di Medicina e Psicologia, Universit\u00e0 La Sapienza, 00185 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giaj-Levra","family":"Niccol\u00f2","sequence":"additional","affiliation":[{"name":"Advanced Radiation Oncology Department, IRCCS Sacro Cuore Don Calabria Hospital, Cancer Care Center, 37024 Verona, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Lohr","sequence":"additional","affiliation":[{"name":"Radiation Oncology Department, Centre L\u00e8on B\u00e8rard, 693736 Lyon, France"},{"name":"Department of Medical and Surgical Science, University of Modena and Reggio Emilia, 41125 Modena, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cinzia","family":"Iotti","sequence":"additional","affiliation":[{"name":"Radiation Oncology Unit, Azienda USL-IRCCS di Reggio Emilia, 42123 Reggio Emilia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrizia","family":"Ciammella","sequence":"additional","affiliation":[{"name":"Radiation Oncology Unit, Azienda USL-IRCCS di Reggio Emilia, 42123 Reggio Emilia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,1,10]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1016\/S0140-6736(11)60165-7","article-title":"Small-cell lung cancer","volume":"378","author":"VanMeerbeeck","year":"2011","journal-title":"Lancet"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1056\/NEJMoa071780","article-title":"Prophylactic cranial irradiation in extensive small-cell lung cancer","volume":"357","author":"Slotman","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1097\/00001622-199104000-00011","article-title":"Diagnosis, staging, and prognostic factors of small cell lung cancer","volume":"3","author":"Stahel","year":"1991","journal-title":"Curr. Opin. Oncol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/j.jtho.2015.10.008","article-title":"The International Association for the Study of Lung Cancer Staging Project: Proposals for the revision of the clinical and pathologic staging of small cell lung cancer in the forthcoming eight edition of the TNM classification for lung cancer","volume":"11","author":"Nicholson","year":"2015","journal-title":"J. Thorac. Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1200\/JCO.1985.3.11.1471","article-title":"VP-16 and cisplatin as first-line therapy for small-cell lung cancer","volume":"3","author":"Evans","year":"1985","journal-title":"J. Clin. Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1056\/NEJMoa1809064","article-title":"First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer","volume":"379","author":"Horn","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"v710","DOI":"10.1093\/annonc\/mdz264","article-title":"IMpower133: Updated overall survival (OS) analysis of first-line (1 L) atezolizumab (atezo) + carboplatin + etoposide in extensive-stage SCLC (ES-SCLC)","volume":"30","author":"Reck","year":"2019","journal-title":"Ann. Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1016\/S0140-6736(19)32222-6","article-title":"Durvalumab plus platinum\u2013etoposide versus platinum\u2013etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): A randomised, controlled, open-label, phase 3 trial","volume":"394","author":"Dvorkin","year":"2019","journal-title":"Lancet"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"9002","DOI":"10.1200\/JCO.2020.38.15_suppl.9002","article-title":"Durvalumab \u00b1 tremelimumab + platinum-etoposide in first-line extensive-stage SCLC (ES-SCLC): Updated results from the phase III CASPIAN study","volume":"38","author":"Dvorkin","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"JCO2000793","DOI":"10.1200\/JCO.20.00793","article-title":"Pembrolizumab or Placebo Plus Etoposide and Platinum as First-Line Therapy for Extensive-Stage Small-Cell Lung Cancer: Randomized, Double-Blind, Phase III KEYNOTE-604 Study","volume":"38","author":"Rudin","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"3740","DOI":"10.1200\/JCO.2016.67.6601","article-title":"Phase III randomized trial of ipilimumab plus etoposide and platinum versus placebo plus etoposide and platinum in extensive-stage small-cell lung cancer","volume":"34","author":"Reck","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1093\/annonc\/mds213","article-title":"Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer: Results from a randomized, double-blind, multicenter phase 2 trial","volume":"24","author":"Reck","year":"2013","journal-title":"Ann. Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"744956","DOI":"10.3389\/fonc.2021.744956","article-title":"A Real-World, Multicenter, Observational Retrospective Study of Durvalumab after Concomitant or Sequential Chemoradiation for Unresectable Stage III Non-Small Cell Lung Cancer","volume":"11","author":"Bruni","year":"2021","journal-title":"Front. Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"LBA86","DOI":"10.1016\/j.annonc.2020.08.2328","article-title":"Durvalumab (D) \u00b1 tremelimumab + platinum\u2013etoposide in first-line extensive-stage small cell lung cancer: Characterization of long-term clinical benefit of tumour mutational burden in CASPIAN","volume":"31","author":"Goldman","year":"2020","journal-title":"Ann. Oncol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1200\/JCO.20.00793","article-title":"KEYNOTE-604: Pembrolizumab (pembro) or placebo plus etopide and platinum (EP) as first-line therapy for extensive-stage (ES) small-cell lung cancer (SCLC)","volume":"38","author":"Rudin","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1782MO","DOI":"10.1016\/j.annonc.2020.08.1544","article-title":"Health-related quality of life in KEYNOTE604: Pembrolizumab (pembro) or placebo added to etoposide and platinum as first-line therapy for extensive-stage small cell lung cancer","volume":"31","author":"Kim","year":"2020","journal-title":"Ann. Oncol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"746853","DOI":"10.3389\/fphar.2021.746853","article-title":"Biological Bases of Immune-Related Adverse Events and Potential Crosslinks with Immunogenic Effects of Radiation","volume":"12","author":"Bardoscia","year":"2021","journal-title":"Front. Pharmacol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"4539","DOI":"10.1200\/JCO.2005.04.4859","article-title":"Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: Analysis of the surveillance, epidemiologic, and end results database","volume":"24","author":"Govindan","year":"2006","journal-title":"J. Clin. Oncol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"e400S","DOI":"10.1378\/chest.12-2363","article-title":"Treatment of small cell lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines","volume":"143","author":"Jett","year":"2013","journal-title":"Chest"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1056\/NEJM199908123410703","article-title":"Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. Prophylactic Cranial Irradiation Overview Collaborative Group","volume":"341","author":"Arriagada","year":"1999","journal-title":"N. Engl. J. Med."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/S1470-2045(17)30230-9","article-title":"Prophylactic cranial irradiation versus observation in patients with extensive-disease small-cell lung cancer: A multicentre, randomised, open-label, phase 3 trial","volume":"18","author":"Takahashi","year":"2017","journal-title":"Lancet Oncol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/S0140-6736(14)61085-0","article-title":"Use of thoracic radiotherapy for extensive stage small-cell lung cancer: A phase 3 randomised controlled trial","volume":"385","author":"Slotman","year":"2015","journal-title":"Lancet"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","article-title":"New guidelines to evaluate the response to treatment in solid tumors","volume":"92","author":"Therasse","year":"2000","journal-title":"Natl. Cancer Inst."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.1016\/j.ejca.2014.06.002","article-title":"Validation of standard definition of sensitive versus refractory relapsed small cell lung cancer: A pooled analysis of topotecan second-line trials","volume":"50","author":"Ardizzoni","year":"2014","journal-title":"Eur. J. Cancer"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"5423","DOI":"10.1002\/cncr.26206","article-title":"Thoracic radiotherapy improves the overall survival of patients with extensive-stage small cell lung cancer with distant metastasis","volume":"117","author":"Zhu","year":"2011","journal-title":"Cancer"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/s13014-021-01773-x","article-title":"Clinical outcomes of extensive-stage small cell lung cancer patients treated with thoracic radiotherapy at different times and fractionations","volume":"16","author":"Han","year":"2021","journal-title":"Radiat. Oncol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1016\/j.jtho.2017.06.015","article-title":"Randomized Phase II Study Comparing Prophylactic Cranial Irradiation Alone to Prophylactic Cranial Irradiation and Consolidative Extracranial Irradiation for Extensive-Disease Small Cell Lung Cancer (ED SCLC): NRG Oncology RTOG 0937","volume":"12","author":"Gore","year":"2017","journal-title":"J. Thorac. Oncol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1002\/cncr.24105","article-title":"Evaluation of the use of prophylactic cranial irradiation in small cell lung cancer","volume":"115","author":"Patel","year":"2009","journal-title":"Cancer"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1","DOI":"10.5603\/RPOR.a2021.0129","article-title":"Special stereotactic radiotherapy techniques: Procedures and equipment for treatment simulation and dose delivery","volume":"27","author":"Paoletti","year":"2022","journal-title":"Rep. Pract. Oncol. Radiother."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"102894","DOI":"10.1016\/j.critrevonc.2020.102894","article-title":"The use of radiation therapy for oligoprogressive\/oligopersistent oncogene-driven non-small cell lung cancer: State of the art","volume":"148","author":"Franceschini","year":"2020","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Cozzi, S., Al\u00ec, E., Bardoscia, L., Najafi, M., Botti, A., Blandino, G., Giaccherini, L., Ruggieri, M.P., Augugliaro, M., and Iori, F. (2022). Stereotactic Body Radiation Therapy (SBRT) for Oligorecurrent\/Oligoprogressive Mediastinal and Hilar Lymph Node Metastasis: A Systematic Review. Cancers, 14.","DOI":"10.3390\/cancers14112680"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"103500","DOI":"10.1016\/j.critrevonc.2021.103500","article-title":"Thoracic re-irradiation with 3D-conformal or more advanced techniques: A systematic review of treatment safety by the Re-irradiation Study Group of the Italian Association of Radiation and Oncology AIRO","volume":"167","author":"Maddalo","year":"2021","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1016\/j.jtho.2016.05.028","article-title":"Outcome and biomarker analysis from a multicentre phase 2 study of ipilimumab in combination with carboplatin and etoposide as first-line therapy for extensive-stage SCLC","volume":"11","author":"Arriola","year":"2016","journal-title":"J. Thorac. Oncol."},{"key":"ref_34","first-page":"1718MO","article-title":"IMpower 133: Characterisation of long-term survivors treated first-line with chemotherapy\u2013atezolizumab in extensive-stage small cell lung cancer","volume":"31","author":"Horn","year":"2020","journal-title":"Ann. Oncol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.annonc.2019.10.021","article-title":"Safety and patient-reported outcomes of atezolizumab, carboplatin, and etoposide in extensive-stage small-cell lung cancer (IMpower133): A randomized phase I\/III trial","volume":"31","author":"Mansfield","year":"2020","journal-title":"Ann. Oncol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1200\/JCO.2020.38.15_suppl.9000","article-title":"Randomized phase II clinical trial of cisplatin\/carboplatin and etoposide (CE) alone or in combination with nivolumab as frontline therapy for extensive-stage small cell lung cancer (ES-SCLC): ECOG-ACRIN EA5161","volume":"38","author":"Leal","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"LBA85","DOI":"10.1016\/j.annonc.2020.08.2327","article-title":"REACTION: A phase II study of etoposide and cis\/carboplatin with or without pembrolizumab in untreated extensive small cell lung cancer","volume":"31","author":"Besse","year":"2020","journal-title":"Ann. Oncol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"3018","DOI":"10.3389\/fimmu.2018.03018","article-title":"Potential Role of CXCR4 Targeting in the Context of Radiotherapy and Immunotherapy of Cancer","volume":"9","author":"Eckert","year":"2018","journal-title":"Front. Immunol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"e466","DOI":"10.1016\/j.ijrobp.2021.07.1303","article-title":"Role of Thoracic Radiotherapy in Extensive Stage Small Cell Lung Cancer (ES-SCLC) in the Immunotherapy Era: A National Hospital-Based Registry Analysis","volume":"111","author":"Gross","year":"2021","journal-title":"Int. J. Radiat. Oncol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.jtho.2019.10.001","article-title":"Phase I Trial of Pembrolizumab and Radiation Therapy after Induction Chemotherapy for Extensive-Stage Small Cell Lung Cancer","volume":"15","author":"Welsh","year":"2020","journal-title":"J. Thorac. Oncol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"S36","DOI":"10.1016\/j.ijrobp.2019.06.452","article-title":"A prospective Single Arm Phase I\/II Study: Consolidative Ipilimumab and Nivolumab with Thoracic Radiotherapy after Platinum Based Chemotherapy for Patients with Extensive Stage Small Cell Lung Cancer","volume":"105","author":"Perez","year":"2019","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_42","first-page":"1000883","article-title":"Consolidative Thoracic Radiation Therapy after First-line Chemotherapy and Immunotherapy in Extensive-Stage Small Cell Lung Cancer: A Multi-institutional Case Series","volume":"7","author":"Diamond","year":"2022","journal-title":"Adv. Radiat. Oncol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"210079","DOI":"10.1183\/16000617.0079-2021","article-title":"Recent developments in the treatment of small cell lung cancer","volume":"30","author":"Hiddinga","year":"2021","journal-title":"Eur. Respir. Rev."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/15\/2\/434\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T18:05:08Z","timestamp":1760119508000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/15\/2\/434"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,10]]},"references-count":43,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2023,1]]}},"alternative-id":["cancers15020434"],"URL":"https:\/\/doi.org\/10.3390\/cancers15020434","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,10]]}}}